Indian Journal of Cancer Home 

CASE REPORT
[View FULLTEXT] [Download PDF]
Year : 2019  |  Volume : 56  |  Issue : 3  |  Page : 274--275

TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study

Linu A Jacob1, Gowhar Shafi2 
1 Department of Medical Oncology, Fortis Hospital, Bengaluru, Karnataka, India
2 Department of Clinical Genomics and Bioinformatics, Positive Bioscience, Mumbai, Maharashtra, India

Correspondence Address:
Linu A Jacob
Department of Medical Oncology, Fortis Hospital, Bengaluru, Karnataka
India

We report a case of a 67-year-old man with pazopanib-resistant metastatic renal cell carcinoma (mRCC) who showed an exceptional response to everolimus. Furthermore, this patient had TSC1 and TSC2 mutations. Only a subset of patients with mRCC respond to mTOR inhibitors and emerging evidences indicate that TSC1 and TSC2 mutations could be markers of response to mTOR inhibition. The current case study supports these accruing evidences.


How to cite this article:
Jacob LA, Shafi G. TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study.Indian J Cancer 2019;56:274-275


How to cite this URL:
Jacob LA, Shafi G. TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study. Indian J Cancer [serial online] 2019 [cited 2020 Feb 25 ];56:274-275
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2019;volume=56;issue=3;spage=274;epage=275;aulast=Jacob;type=0